Mark has over 30 years of experience in biotech as a scientist and technologist and has a successful track history of building strong integrated multidisciplinary teams. At Valo, Mark is responsible for overseeing the company’s Lexington site operations, a hub for early discovery capabilities of Valo’s Opal Computational Platform™️, which includes compound purification, in vitro ADME (absorption, distribution, metabolism, and excretion), and lab informatics supporting rapid Design-Make-Test-Analyze (DMTA) cycles to accelerate early discovery leads toward becoming development candidates. In addition, he plays a lead role in the company’s CMC (Chemistry, Manufacturing, and Controls) function and support of Valo’s clinical development efforts.

Mark joined Valo in 2020 after 12 years at Forma Therapeutics when its Early Discovery group was acquired. At Forma, Mark played a leadership role in establishing the chemistry analytical & purification technology platform supporting automated small molecule synthesis and DNA-encoded library functions, in vitro ADME screening, and management of an internal high-throughput screening library of 500,000 compounds. Mark was the analytical lead in the CMC group that successfully oversaw six INDs in six years, including olutasidenib for use in oncology and etavopivat for the treatment of sickle cell disease.

Before Forma, Mark held various analytical sciences roles at companies such as Neurogen Corporation in Connecticut, Tripos Receptor Research, and Celltech Ltd. At Neurogen, he helped build the Accelerated Integrated Drug Discovery (AIDD) platform and an internal synthesis library of one million compounds. Mark holds a BSc (Hons) from the University of Salford, England.